[HTML][HTML] Efficacy of tocilizumab in patients hospitalized with Covid-19
JH Stone, MJ Frigault, NJ Serling-Boyd… - … England Journal of …, 2020 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow… - Cancer research, 2011 - AACR
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are
effective treatments in preclinical models and in cancer patients with ALK-translocated …
effective treatments in preclinical models and in cancer patients with ALK-translocated …
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for
treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic …
treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic …
[HTML][HTML] Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
CA Jacobson, BD Hunter, R Redd… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug
Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of …
Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of …
[HTML][HTML] Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma
CJ Gibson, RC Lindsley, V Tchekmedyian… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition
characterized by somatic mutations in the blood of otherwise healthy adults. We …
characterized by somatic mutations in the blood of otherwise healthy adults. We …
[HTML][HTML] Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
EB Esrick, LE Lehmann, A Biffi, M Achebe… - … England Journal of …, 2021 - Mass Medical Soc
Background Sickle cell disease is characterized by hemolytic anemia, pain, and progressive
organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising α-and γ …
organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising α-and γ …
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line
L Gradoville, J Gerlach, E Grogan, D Shedd… - Journal of …, 2000 - Am Soc Microbiol
Rta, the gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) encoded mainly
in open reading frame 50 (ORF50), is capable of activating expression of viral lytic cycle …
in open reading frame 50 (ORF50), is capable of activating expression of viral lytic cycle …
Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma
SH Baumeister, J Murad, L Werner, H Daley… - Cancer immunology …, 2019 - AACR
NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or
poorly expressed on healthy tissues. We conducted a phase I dose-escalation study to …
poorly expressed on healthy tissues. We conducted a phase I dose-escalation study to …
[HTML][HTML] Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States
CA Jacobson, FL Locke, L Ma, J Asubonteng… - … and cellular therapy, 2022 - Elsevier
Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …